

Annette G Beck-Sickinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9364927/publications.pdf>

Version: 2024-02-01

349
papers

13,467
citations

19657

61
h-index

46799

89
g-index

376
all docs

376
docs citations

376
times ranked

11775
citing authors

#	ARTICLE	IF	CITATIONS
1	The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. <i>European Journal of Pharmacology</i> , 1994, 271, R11-R13.	3.5	343
2	Multiple Peptide Synthesis Methods and Their Applications. <i>New Synthetic Methods(87)</i> . <i>Angewandte Chemie International Edition in English</i> , 1992, 31, 367-383.	4.4	284
3	Peptide chemistry toolbox – Transforming natural peptides into peptide therapeutics. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2759-2765.	3.0	214
4	Automated solid-phase peptide synthesis to obtain therapeutic peptides. <i>Beilstein Journal of Organic Chemistry</i> , 2014, 10, 1197-1212.	2.2	179
5	Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. , 2000, 6, 97-122.		176
6	Neuropeptide ϵ Y stimulates neuronal precursor proliferation in the postnatal and adult dentate gyrus. <i>Journal of Neurochemistry</i> , 2005, 93, 560-570.	3.9	174
7	Complete L-Alanine Scan of Neuropeptide Y Reveals Ligands Binding to Y1 and Y2 Receptors with Distinguished Conformations. <i>FEBS Journal</i> , 1994, 225, 947-958.	0.2	167
8	The First Selective Agonist for the Neuropeptide Y5 Receptor Increases Food Intake in Rats. <i>Journal of Biological Chemistry</i> , 2000, 275, 36043-36048.	3.4	167
9	Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells. <i>Journal of Neurochemistry</i> , 2003, 86, 646-659.	3.9	166
10	Peptide-tags for site-specific protein labelling in vitro and in vivo. <i>Molecular BioSystems</i> , 2016, 12, 1731-1745.	2.9	152
11	Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. <i>Frontiers in Chemistry</i> , 2020, 8, 571.	3.6	143
12	Expressed protein ligation. <i>FEBS Journal</i> , 2004, 271, 663-677.	0.2	135
13	Structure and Dynamics of Micelle-bound Neuropeptide Y: Comparison with Unligated NPY and Implications for Receptor Selection. <i>Journal of Molecular Biology</i> , 2001, 305, 307-329.	4.2	129
14	Decoding the Entry of Two Novel Cell-Penetrating Peptides in HeLa Cells: A Lipid Raft-Mediated Endocytosis and Endosomal Escape. <i>Biochemistry</i> , 2005, 44, 72-81.	2.5	129
15	Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors. <i>Biopolymers</i> , 1995, 37, 123-142.	2.4	127
16	Peptides and peptide conjugates: therapeutics on the upward path. <i>Future Medicinal Chemistry</i> , 2012, 4, 1567-1586.	2.3	125
17	Vaspin inhibits kallikrein 7 by serpin mechanism. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 2569-2583.	5.4	125
18	Neuropeptide Y receptors: how to get subtype selectivity. <i>Frontiers in Endocrinology</i> , 2013, 4, 5.	3.5	124

#	ARTICLE	IF	CITATIONS
19	Characterization of the interaction of interleukin-8 with hyaluronan, chondroitin sulfate, dermatan sulfate and their sulfated derivatives by spectroscopy and molecular modeling. <i>Glycobiology</i> , 2012, 22, 134-145.	2.5	120
20	Homodimerization of Neuropeptide Y Receptors Investigated by Fluorescence Resonance Energy Transfer in Living Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 10562-10571.	3.4	117
21	Processing, signaling, and physiological function of chemerin. <i>IUBMB Life</i> , 2014, 66, 19-26.	3.4	116
22	Overlapping Gene Structure of the Human Neuropeptide Y Receptor Subtypes Y1 and Y5 Suggests Coordinate Transcriptional Regulation. <i>Genomics</i> , 1997, 41, 315-319.	2.9	114
23	The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y ₂ and not Y ₅ receptors. <i>European Journal of Neuroscience</i> , 2005, 22, 1417-1430.	2.6	114
24	Biosynthesis of the lantibiotic Pep5. Isolation and characterization of a prepeptide containing dehydroamino acids. <i>FEBS Journal</i> , 1990, 194, 217-223.	0.2	111
25	Epitope mapping of the <i>Dermatophagoides pteronyssinus</i> house dust mite major allergen Der p II using overlapping synthetic peptides. <i>Molecular Immunology</i> , 1991, 28, 1225-1232.	2.2	105
26	Biochemical Characterisation and Genetic Analysis of Aureocin A53, a New, Atypical Bacteriocin from <i>Staphylococcus aureus</i> . <i>Journal of Molecular Biology</i> , 2002, 319, 745-756.	4.2	104
27	Neuropeptide Y (NPY) Suppresses Experimental Autoimmune Encephalomyelitis: NPY1 Receptor-Specific Inhibition of Autoreactive Th1 Responses In Vivo. <i>Journal of Immunology</i> , 2003, 171, 3451-3458.	0.8	103
28	Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor. <i>Nature</i> , 2018, 556, 520-524.	27.8	100
29	In vitro and in vivo evaluation of a ^{99m} Tc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. <i>Nuclear Medicine and Biology</i> , 2002, 29, 553-560.	0.6	98
30	Novel Peptide Conjugates for Tumor-Specific Chemotherapy. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1341-1348.	6.4	96
31	Glutamate release by neurons evokes a purinergic inhibitory mechanism of osmotic glial cell swelling in the rat retina: Activation by neuropeptide Y. <i>Journal of Neuroscience Research</i> , 2006, 83, 538-550.	2.9	93
32	Comparison of the photochemical behavior of four different photoactivatable probes. <i>Chemical Biology and Drug Design</i> , 1997, 49, 375-383.	1.1	91
33	Chemical and biological characterization of new Re(CO) ₃ [^{99m} Tc](CO) ₃ bombesin analogues. <i>Nuclear Medicine and Biology</i> , 2007, 34, 17-28.	0.6	89
34	Novel analogues of neuropeptide Y with a preference for the Y1-receptor. <i>FEBS Journal</i> , 2001, 268, 2828-2837.	0.2	88
35	A fast and inexpensive method for N-terminal fluorescein-labeling of peptides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 597-600.	2.2	87
36	Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. <i>Biological Chemistry</i> , 2010, 391, 1005-18.	2.5	87

#	ARTICLE	IF	CITATIONS
37	Peptide $\hat{\text{I}}$ thioester formation using standard Fmoc-chemistry. <i>Tetrahedron Letters</i> , 2003, 44, 3551-3554.	1.4	85
38	Drug delivery and release systems for targeted tumor therapy. <i>Journal of Peptide Science</i> , 2015, 21, 186-200.	1.4	84
39	Translocation of Human Calcitonin in Respiratory Nasal Epithelium Is Associated with Self-Assembly in Lipid Membrane. <i>Biochemistry</i> , 1998, 37, 16582-16590.	2.5	82
40	Ghrelin Receptor Inverse Agonists: Identification of an Active Peptide Core and Its Interaction Epitopes on the Receptor. <i>Molecular Pharmacology</i> , 2006, 70, 936-946.	2.3	82
41	Peptide drugs to target G protein-coupled receptors. <i>Trends in Pharmacological Sciences</i> , 2010, 31, 434-441.	8.7	82
42	Receptor Subtype-specific Docking of Asp ^{6.59} with C-terminal Arginine Residues in Y Receptor Ligands. <i>Journal of Biological Chemistry</i> , 2007, 282, 7543-7551.	3.4	81
43	Analogues of Neuropeptide Y Containing $\hat{\text{I}}^2$ -Aminocyclopropane Carboxylic Acids are the Shortest Linear Peptides That Are Selective for the Y ₁ Receptor. <i>Angewandte Chemie - International Edition</i> , 2003, 42, 202-205.	13.8	79
44	Breast Cancer Diagnosis by Neuropeptide Y Analogues: From Synthesis to Clinical Application. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 1155-1158.	13.8	76
45	Neuropeptide Y ₁ and Y ₅ Receptors Mediate the Effects of Neuropeptide Y on the Hypothalamic-Pituitary-Thyroid Axis. <i>Endocrinology</i> , 2002, 143, 4513-4519.	2.8	75
46	Structure-Activity Studies of Orexin A and Orexin B at the Human Orexin 1 and Orexin 2 Receptors Led to Orexin 2 Receptor Selective and Orexin 1 Receptor Preferring Ligands. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1153-1160.	6.4	74
47	Unwinding of the C-terminal Residues of Neuropeptide Y is critical for Y ₂ Receptor Binding and Activation. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 7446-7449.	13.8	74
48	Identification of an Efficacy Switch Region in the Ghrelin Receptor Responsible for Interchange between Agonism and Inverse Agonism. <i>Journal of Biological Chemistry</i> , 2007, 282, 15799-15811.	3.4	73
49	Isotope-labeled cross-linkers and fourier transform ion cyclotron resonance mass spectrometry for structural analysis of a protein/peptide complex. <i>Journal of the American Society for Mass Spectrometry</i> , 2006, 17, 1100-1113.	2.8	72
50	Artificial Chemokines: Combining Chemistry and Molecular Biology for the Elucidation of Interleukin-8 Functionality. <i>Journal of the American Chemical Society</i> , 2008, 130, 15311-15317.	13.7	72
51	Peptide-templated Acyl Transfer: A Chemical Method for the Labeling of Membrane Proteins on Live Cells. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 10237-10241.	13.8	71
52	Structural characterization and binding sites of G-protein-coupled receptors. <i>Drug Discovery Today</i> , 1996, 1, 502-513.	6.4	69
53	Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development. <i>Journal of Peptide Science</i> , 2011, 17, 233-246.	1.4	69
54	Amino Acid Side Chain Attachment Approach and Its Application to the Synthesis of Tyrosine-Containing Cyclic Peptides. <i>Journal of Organic Chemistry</i> , 1999, 64, 4353-4361.	3.2	68

#	ARTICLE	IF	CITATIONS
55	Metabolic cleavage of cell-penetrating peptides in contact with epithelial models: human calcitonin (hCT)-derived peptides, Tat(47-57) and penetratin(43-58). <i>Biochemical Journal</i> , 2004, 382, 945-956.	3.7	68
56	Long-Acting Lipidated Analogue of Human Pancreatic Polypeptide Is Slowly Released into Circulation. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2658-2667.	6.4	68
57	Developing novel hCT derived cell-penetrating peptides with improved metabolic stability. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2006, 1758, 347-354.	2.6	67
58	Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation. <i>Journal of Experimental Medicine</i> , 2008, 205, 1435-1446.	8.5	66
59	Illuminating the life of GPCRs. <i>Cell Communication and Signaling</i> , 2009, 7, 16.	6.5	66
60	Molecular recognition of the NPY hormone family by their receptors. <i>Nutrition</i> , 2008, 24, 907-917.	2.4	64
61	^{99m} Tc-Labeled Neuropeptide Y Analogues as Potential Tumor Imaging Agents. <i>Bioconjugate Chemistry</i> , 2001, 12, 1028-1034.	3.6	63
62	Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus. <i>Cellular Signalling</i> , 2008, 20, 1740-1749.	3.6	63
63	A novel, biased-like SDF-1 derivative acts synergistically with starPEG-based heparin hydrogels and improves eEPC migration in vitro. <i>Journal of Controlled Release</i> , 2012, 162, 68-75.	9.9	62
64	From Micromolar to Nanomolar Affinity: A Systematic Approach To Identify the Binding Site of CGRP at the Human Calcitonin Gene-Related Peptide 1 Receptor. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 117-123.	6.4	61
65	Multifunctional Coating Improves Cell Adhesion on Titanium by using Cooperatively Acting Peptides. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 4826-4830.	13.8	61
66	Incorporation of <i>ortho</i> -Carbaboranyl- <i>N</i> - μ -Modified <i>l</i> -Lysine into Neuropeptide Y Receptor Y ₁ - and Y ₂ -Selective Analogues. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2368-2377.	6.4	60
67	R ^F amide Peptides: Structure, Function, Mechanisms and Pharmaceutical Potential. <i>Pharmaceuticals</i> , 2011, 4, 1248-1280.	3.8	60
68	Cellular Uptake But Low Permeation of Human Calcitonin-Derived Cell Penetrating Peptides and Tat(47-57) Through Well-Differentiated Epithelial Models. <i>Pharmaceutical Research</i> , 2004, 21, 1248-1256.	3.5	59
69	Adrenomedullin – new perspectives of a potent peptide hormone. <i>Journal of Peptide Science</i> , 2017, 23, 472-485.	1.4	59
70	Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery. <i>Endocrinology</i> , 2016, 157, 3482-3492.	2.8	58
71	Multiple NPY Receptors Inhibit GABA _A Synaptic Responses of Rat Medial Parvocellular Effector Neurons in the Hypothalamic Paraventricular Nucleus. <i>Endocrinology</i> , 2002, 143, 535-543.	2.8	55
72	A novel cyclic analog of neuropeptide Y specific for the Y ₂ receptor. <i>FEBS Journal</i> , 1992, 206, 957-964.	0.2	54

#	ARTICLE	IF	CITATIONS
73	Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors. <i>Regulatory Peptides</i> , 2005, 124, 163-172.	1.9	53
74	Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2008, 8, 186-199.	1.7	53
75	Novel Chemically Modified Analogues of Neuropeptide Y for Tumor Targeting. <i>Bioconjugate Chemistry</i> , 2008, 19, 1430-1438.	3.6	52
76	Receptor-Mediated Uptake of Boron-Rich Neuropeptide Y Analogues for Boron Neutron Capture Therapy. <i>ChemMedChem</i> , 2015, 10, 164-172.	3.2	52
77	Role of Prohormone Convertases in Pro-Neuropeptide Y Processing: Coexpression and in Vitro Kinetic Investigations. <i>Biochemistry</i> , 1997, 36, 16309-16320.	2.5	51
78	Protein kinase CK2 interacts with adiponectin receptor 1 and participates in adiponectin signaling. <i>Cellular Signalling</i> , 2009, 21, 936-942.	3.6	51
79	Optimization of capillary electrophoresis of mixtures of basic peptides and comparison with HPLC. <i>Analytical Chemistry</i> , 1993, 65, 1399-1405.	6.5	50
80	Role of a hydrophobic pocket of the human Y1 neuropeptide Y receptor in ligand binding. <i>Molecular and Cellular Endocrinology</i> , 1995, 112, 215-222.	3.2	50
81	Presence of neuropeptide Y and the Y1 receptor in the plasma membrane and nuclear envelope of human endocardial endothelial cells: modulation of intracellular calcium. <i>Canadian Journal of Physiology and Pharmacology</i> , 2003, 81, 288-300.	1.4	50
82	Guanidine ⁺ Acylguanidine Bioisosteric Approach in the Design of Radioligands: Synthesis of a Tritium-Labeled ³ H-Propionylargininamide ([³ H]-UR-MK114) as a Highly Potent and Selective Neuropeptide Y ₁ Receptor Antagonist. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 8168-8172.	6.4	50
83	Peptide mini-scaffold facilitates JNK3 activation in cells. <i>Scientific Reports</i> , 2016, 6, 21025.	3.3	50
84	Neuropeptide Y5 Receptors Reduce Synaptic Excitation in Proximal Subiculum, But Not Epileptiform Activity in Rat Hippocampal Slices. <i>Journal of Neurophysiology</i> , 2000, 83, 723-734.	1.8	49
85	Cellular Internalization of Enhanced Green Fluorescent Protein Ligated to a Human Calcitonin-Based Carrier Peptide. <i>ChemBioChem</i> , 2002, 3, 672.	2.6	49
86	Neuropeptide Y: identification of the binding site. <i>International Journal of Peptide and Protein Research</i> , 1990, 36, 522-530.	0.1	49
87	Ghrelin Receptor. <i>Methods in Enzymology</i> , 2010, 485, 103-121.	1.0	49
88	The Adipocytokine Nampt and Its Product NMN Have No Effect on Beta-Cell Survival but Potentiate Glucose Stimulated Insulin Secretion. <i>PLoS ONE</i> , 2013, 8, e54106.	2.5	49
89	Live cell PNA labelling enables erasable fluorescence imaging of membrane proteins. <i>Nature Chemistry</i> , 2021, 13, 15-23.	13.6	48
90	Monitoring of the internalization of neuropeptide Y on neuroblastoma cell line SK-N-MC. <i>FEBS Journal</i> , 2000, 267, 5631-5637.	0.2	47

#	ARTICLE	IF	CITATIONS
91	Blockade of neuropeptide Y ₂ receptors and suppression of NPY's anti-epileptic actions in the rat hippocampal slice by BIIE0246. <i>British Journal of Pharmacology</i> , 2002, 136, 502-509.	5.4	47
92	Structure and Dynamics of Helix-0 of the N-BAR Domain in Lipid Micelles and Bilayers. <i>Biophysical Journal</i> , 2008, 95, 4315-4323.	0.5	47
93	Microscopic Mechanism of Specific Peptide Adhesion to Semiconductor Substrates. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 9530-9533.	13.8	47
94	Proteolytic activation of prochemerin by kallikrein 7 breaks an ionic linkage and results in C-terminal rearrangement. <i>Biochemical Journal</i> , 2013, 452, 271-280.	3.7	47
95	Structural Model of Ghrelin Bound to its G Protein-Coupled Receptor. <i>Structure</i> , 2019, 27, 537-544.e4.	3.3	47
96	Structure/activity relationships of C-terminal neuropeptide Y peptide segments and analogues composed of sequence 1-4 linked to 25-36. <i>FEBS Journal</i> , 1990, 194, 449-456.	0.2	46
97	Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26). <i>Journal of Neuroimmunology</i> , 2002, 129, 35-42.	2.3	46
98	Multifunctional biomaterial coatings: synthetic challenges and biological activity. <i>Biological Chemistry</i> , 2017, 398, 3-22.	2.5	46
99	NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor activation in vivo: sympathetic co-transmission during leukocyte mobilization. <i>Journal of Neuroimmunology</i> , 2002, 132, 25-33.	2.3	43
100	Specifically Immobilised Aldo/Keto Reductase AKR1A1 Shows a Dramatic Increase in Activity Relative to the Randomly Immobilised Enzyme. <i>ChemBioChem</i> , 2007, 8, 1071-1076.	2.6	43
101	Ghrelin—a novel generation of anti-obesity drug: design, pharmacomodulation and biological activity of ghrelin analogues. <i>Journal of Peptide Science</i> , 2009, 15, 711-730.	1.4	43
102	Mutations in arrestin-3 differentially affect binding to neuropeptide Y receptor subtypes. <i>Cellular Signalling</i> , 2014, 26, 1523-1531.	3.6	43
103	“36[K4,RYYS19”23]PP a novel Y5-receptor preferring ligand with strong stimulatory effect on food intake. <i>Regulatory Peptides</i> , 2000, 87, 47-58.	1.9	42
104	In vitro gene delivery by a novel human calcitonin (hCT)-derived carrier peptide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 51-54.	2.2	42
105	Unique Interaction Pattern for a Functionally Biased Ghrelin Receptor Agonist. <i>Journal of Biological Chemistry</i> , 2011, 286, 20845-20860.	3.4	42
106	An Aromatic Region To Induce a Switch between Agonism and Inverse Agonism at the Ghrelin Receptor. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7437-7449.	6.4	42
107	Promiscuous Modification of the Nuclear Poly(A)-binding Protein by Multiple Protein-arginine Methyltransferases Does Not Affect the Aggregation Behavior. <i>Journal of Biological Chemistry</i> , 2008, 283, 20408-20420.	3.4	41
108	Type I Arginine Methyltransferases PRMT1 and PRMT-3 Act Distributively. <i>Journal of Biological Chemistry</i> , 2009, 284, 8274-8282.	3.4	41

#	ARTICLE	IF	CITATIONS
109	Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y ₂ receptor. <i>FEBS Letters</i> , 1996, 394, 169-173.	2.8	40
110	Y1 receptors in the nucleus accumbens: Ultrastructural localization and association with neuropeptide Y. , 1998, 52, 54-68.		40
111	Agonists for neuropeptide Y receptors Y1 and Y5 stimulate different phases of feeding in guinea pigs. <i>British Journal of Pharmacology</i> , 2003, 139, 1433-1440.	5.4	40
112	Investigation of lysine side chain interactions of interleukin-8 with heparin and other glycosaminoglycans studied by a methylation-NMR approach. <i>Glycobiology</i> , 2013, 23, 1260-1269.	2.5	40
113	Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-MSH and setmelanotide. <i>Cell Research</i> , 2021, 31, 1176-1189.	12.0	40
114	Y-receptor affinity modulation by the design of pancreatic polypeptide/neuropeptide Y chimera led to Y5-receptor ligands with picomolar affinity. <i>Peptides</i> , 2001, 22, 365-378.	2.4	39
115	Determination of Affinity and Activity of Ligands at the Human Neuropeptide Y Y4 Receptor by Flow Cytometry and Aequorin Luminescence. <i>Journal of Receptor and Signal Transduction Research</i> , 2007, 27, 217-233.	2.5	39
116	Ligand-induced Internalization and Recycling of the Human Neuropeptide Y2 Receptor Is Regulated by Its Carboxyl-terminal Tail. <i>Journal of Biological Chemistry</i> , 2010, 285, 41578-41590.	3.4	39
117	Dimerization of adiponectin receptor 1 is inhibited by adiponectin. <i>Journal of Cell Science</i> , 2010, 123, 1320-1328.	2.0	39
118	Peptide Modifications Differentially Alter G Protein-Coupled Receptor Internalization and Signaling Bias. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 10067-10071.	13.8	39
119	Selective Neuropeptide Y Conjugates with Maximized Carborane Loading as Promising Boron Delivery Agents for Boron Neutron Capture Therapy. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2358-2371.	6.4	38
120	Targeting of peptide-binding receptors on cancer cells with peptide-drug conjugates. <i>Peptide Science</i> , 2020, 112, e24171.	1.8	38
121	Cellular Internalization of Human Calcitonin Derived Peptides in MDCK Monolayers: A Comparative Study with Tat(47-57) and Penetratin(43-58). <i>Pharmaceutical Research</i> , 2004, 21, 33-42.	3.5	37
122	Structure-Activity Studies of RFamide Peptides Reveal Subtype-Selective Activation of Neuropeptide FF1 and FF2 Receptors. <i>ChemMedChem</i> , 2011, 6, 1081-1093.	3.2	37
123	Towards improved receptor targeting: anterograde transport, internalization and postendocytic trafficking of neuropeptide Y receptors. <i>Biological Chemistry</i> , 2013, 394, 921-936.	2.5	37
124	Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue. <i>Regulatory Peptides</i> , 2004, 120, 205-214.	1.9	36
125	Identification of the Key Residue of Calcitonin Gene Related Peptide (CGRP) 27~37 to Obtain Antagonists with Picomolar Affinity at the CGRP Receptor. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 616-624.	6.4	36
126	Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands. <i>European Journal of Pharmacology</i> , 2006, 551, 10-18.	3.5	36

#	ARTICLE	IF	CITATIONS
127	Asborin Inhibits Aldo/Keto Reductase...1A1. ChemMedChem, 2011, 6, 89-93.	3.2	36
128	A stable <i>meta</i> -carborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor. Journal of Peptide Science, 2018, 24, e3119.	1.4	36
129	A Y2 Receptor Mimetic Aptamer Directed against Neuropeptide Y. Journal of Biological Chemistry, 2002, 277, 11416-11422.	3.4	34
130	Calcitonin-derived peptide carriers: Mechanisms and application. Advanced Drug Delivery Reviews, 2008, 60, 485-498.	13.7	34
131	First selective agonist of the neuropeptide Y ₁ -receptor with reduced size. Journal of Peptide Science, 2009, 15, 856-866.	1.4	34
132	The neuropeptide Y monomer in solution is not folded in the pancreatic-polypeptide fold. Protein Science, 2009, 11, 1834-1844.	7.6	34
133	Controlling Toxicity of Peptide-Drug Conjugates by Different Chemical Linker Structures. ChemMedChem, 2015, 10, 804-814.	3.2	34
134	Synthesis and <i>in Vitro</i> and <i>in Vivo</i> Evaluation of an ¹⁸ F-Labeled Neuropeptide Y Analogue for Imaging of Breast Cancer by PET. Molecular Pharmaceutics, 2015, 12, 1121-1130.	4.6	34
135	Electron paramagnetic resonance backbone dynamics studies on spin-labelled neuropeptide Y analogues. Journal of Peptide Science, 2002, 8, 671-682.	1.4	33
136	Membrane Surface-Associated Helices Promote Lipid Interactions and Cellular Uptake of Human Calcitonin-Derived Cell Penetrating Peptides. Biophysical Journal, 2005, 89, 4056-4066.	0.5	33
137	Double Methotrexate-Modified Neuropeptide Y Analogues Express Increased Toxicity and Overcome Drug Resistance in Breast Cancer Cells. Journal of Medicinal Chemistry, 2016, 59, 3409-3417.	6.4	33
138	Anti-Inflammatory Action of Keratinocyte-Derived Vaspin. American Journal of Pathology, 2016, 186, 639-651.	3.8	33
139	Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y2 receptors. European Journal of Neuroscience, 2007, 25, 1136-1143.	2.6	32
140	The Third Intracellular Loop Stabilizes the Inactive State of the Neuropeptide Y1 Receptor. Journal of Biological Chemistry, 2008, 283, 33337-33346.	3.4	32
141	Biocompatible Silicon Surfaces through Orthogonal Click Chemistries and a High Affinity Silicon Oxide Binding Peptide. Bioconjugate Chemistry, 2012, 23, 2129-2137.	3.6	32
142	Inhibition of Kallikrein-Related Peptidases 7 and 5 by Grafting Serpin Reactive-Center Loop Sequences onto Sunflower Trypsin Inhibitor (SFTI). ChemBioChem, 2016, 17, 719-726.	2.6	32
143	Novel daunorubicin-carrier peptide conjugates derived from human calcitonin segments. Journal of Molecular Recognition, 2003, 16, 280-287.	2.1	31
144	Expressed Enzymatic Ligation for the Semisynthesis of Chemically Modified Proteins. Angewandte Chemie - International Edition, 2003, 42, 4916-4918.	13.8	31

#	ARTICLE	IF	CITATIONS
145	Sulfonation of arginine residues as side reaction in Fmoc-peptide synthesis. <i>International Journal of Peptide and Protein Research</i> , 1991, 38, 25-31.	0.1	31
146	Rapid Covalent Fluorescence Labeling of Membrane Proteins on Live Cells via Coiled-Coil Templated Acyl Transfer. <i>Bioconjugate Chemistry</i> , 2015, 26, 2106-2117.	3.6	31
147	A rational approach for the development of reduced-size analogues of neuropeptide Y with high affinity to the Y1 receptor. <i>Journal of Peptide Science</i> , 1995, 1, 341-348.	1.4	30
148	Biophysical methods to study ligand-receptor interactions of neuropeptide Y. <i>Biopolymers</i> , 2001, 60, 420-437.	2.4	30
149	Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP. <i>Neuropeptides</i> , 2004, 38, 163-174.	2.2	30
150	Interactions of the Human Calcitonin Fragment 9-32 with Phospholipids: A Monolayer Study. <i>Biophysical Journal</i> , 2004, 87, 386-395.	0.5	30
151	Tracking of human Y receptors in living cells: A fluorescence approach. <i>Peptides</i> , 2007, 28, 226-234.	2.4	30
152	A reconstitution protocol for the in vitro folded human G protein-coupled Y2 receptor into lipid environment. <i>Biophysical Chemistry</i> , 2010, 150, 29-36.	2.8	30
153	Design, Evaluation, and Comparison of Ghrelin Receptor Agonists and Inverse Agonists as Suitable Radiotracers for PET Imaging. <i>Bioconjugate Chemistry</i> , 2012, 23, 771-784.	3.6	30
154	Vaspin - a link of obesity and psoriasis?. <i>Experimental Dermatology</i> , 2012, 21, 309-312.	2.9	30
155	Photoactivatable Chemokines - Controlling Protein Activity by Light. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 9550-9553.	13.8	30
156	Syntheses of defined sulfated oligohyaluronans reveal structural effects, diversity and thermodynamics of GAG-protein binding. <i>Chemical Science</i> , 2019, 10, 866-878.	7.4	30
157	A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy. <i>Journal of Organic Chemistry</i> , 2020, 85, 1446-1457.	3.2	30
158	On the synthesis of orexin A: a novel one-step procedure to obtain peptides with two intramolecular disulphide bonds. <i>Journal of Peptide Science</i> , 2000, 6, 387-397.	1.4	29
159	Functional role of the extracellular N-terminal domain of neuropeptide Y subfamily receptors in membrane integration and agonist-stimulated internalization. <i>Cellular Signalling</i> , 2009, 21, 61-68.	3.6	29
160	A G Protein-biased Designer G Protein-coupled Receptor Useful for Studying the Physiological Relevance of Gq/11-dependent Signaling Pathways. <i>Journal of Biological Chemistry</i> , 2016, 291, 7809-7820.	3.4	29
161	The Conformational Equilibrium of the Neuropeptide Y2 Receptor in Bilayer Membranes. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 23854-23861.	13.8	29
162	Natural and synthetic peptide pools: Characterization by sequencing and electrospray mass spectrometry. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1993, 3, 431-436.	2.2	28

#	ARTICLE	IF	CITATIONS
163	Ala ³¹ -Aib ³² : Identification of the Key Motif for High Affinity and Selectivity of Neuropeptide Y at the Y5-Receptor. <i>Biochemistry</i> , 2002, 41, 8043-8049.	2.5	28
164	Large scale modification of biomolecules using immobilized sortase A from <i>Staphylococcus aureus</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 3504-3510.	3.0	28
165	Pancreatic Polypeptide Is Recognized by Two Hydrophobic Domains of the Human Y4 Receptor Binding Pocket. <i>Journal of Biological Chemistry</i> , 2014, 289, 5846-5859.	3.4	28
166	Charge-Compensated Metallocarborane Building Blocks for Conjugation with Peptides. <i>ChemBioChem</i> , 2016, 17, 308-317.	2.6	28
167	±-Helical small molecular size analogues of neuropeptide Y: Structure-activity relationships. <i>Biopolymers</i> , 1991, 31, 613-619.	2.4	27
168	The SK-N-MC cell line expresses an orexin binding site different from recombinant orexin ¹ -type receptor. <i>FEBS Journal</i> , 2002, 269, 1128-1135.	0.2	27
169	Nano-high-performance liquid chromatography in combination with nano-electrospray ionization Fourier transform ion-cyclotron resonance mass spectrometry for proteome analysis. <i>Rapid Communications in Mass Spectrometry</i> , 2003, 17, 1240-1246.	1.5	27
170	Strongly Altered Receptor Binding Properties in PP and NPY Chimeras Are Accompanied by Changes in Structure and Membrane Binding. <i>Biochemistry</i> , 2005, 44, 9255-9264.	2.5	27
171	Matrix Metalloproteinase 9 (MMP-9) Mediated Release of MMP-9 Resistant Stromal Cell-Derived Factor 1 \pm (SDF-1 \pm) from Surface Modified Polymer Films. <i>ACS Applied Materials & Interfaces</i> , 2014, 6, 5891-5899.	8.0	27
172	The structural investigation of glycosaminoglycan binding to CXCL12 displays distinct interaction sites. <i>Glycobiology</i> , 2016, 26, 1209-1221.	2.5	27
173	CGRP 27-37 analogues with high affinity to the CGRP1 receptor show antagonistic properties in a rat blood flow assay. <i>Regulatory Peptides</i> , 1999, 79, 153-158.	1.9	26
174	Semisynthesis and Application of Carboxyfluorescein-Labelled Biologically Active Human Interleukin-8. <i>Biological Chemistry</i> , 2003, 384, 1619-30.	2.5	26
175	Bilayer interaction and localization of cell penetrating peptides with model membranes: A comparative study of a human calcitonin (hCT)-derived peptide with pVEC and pAntp(43-58). <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2005, 1712, 197-211.	2.6	26
176	Generation of Carrier Peptides for the Delivery of Nucleic Acid Drugs in Primary Cells. <i>ChemMedChem</i> , 2008, 3, 241-253.	3.2	26
177	Residue 75 of Interleukin ⁸ is Crucial for its Interactions with Glycosaminoglycans. <i>ChemBioChem</i> , 2012, 13, 2558-2566.	2.6	26
178	Development of Potent and Metabolically Stable APJ Ligands with High Therapeutic Potential. <i>ChemMedChem</i> , 2016, 11, 2378-2384.	3.2	26
179	Facile and Selective Nanoscale Labeling of Peptides in Solution by Using Photolabile Protecting Groups. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4369-4372.	6.4	25
180	Microelectrode chip based real time monitoring of vital MCF-7 mamma carcinoma cells by impedance spectroscopy. <i>Biosensors and Bioelectronics</i> , 2008, 24, 253-259.	10.1	25

#	ARTICLE	IF	CITATIONS
181	GPC Receptors and Not Ligands Decide the Binding Mode in Neuropeptide Y Multireceptor/Multiligand System. <i>Biochemistry</i> , 2008, 47, 5905-5914.	2.5	25
182	Prokaryotic expression, in vitro folding, and molecular pharmacological characterization of the neuropeptide Y receptor type 2. <i>Biotechnology Progress</i> , 2009, 25, 1732-1739.	2.6	25
183	Determination of G-protein-coupled receptor oligomerization by molecular brightness analyses in single cells. <i>Nature Protocols</i> , 2021, 16, 1419-1451.	12.0	25
184	Improving the Tumor Uptake of ^{99m} Tc-Labeled Neuropeptides Using Stabilized Peptide Analogues. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 181-188.	1.0	24
185	Membrane interaction of neuropeptide Y detected by EPR and NMR spectroscopy. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2005, 1714, 103-113.	2.6	24
186	Structural basis for ligand recognition of the neuropeptide Y Y2 receptor. <i>Nature Communications</i> , 2021, 12, 737.	12.8	24
187	Structure-affinity studies of C-terminally modified analogs of neuropeptide Y led to a novel class of peptidic Y1 receptor antagonist. <i>Regulatory Peptides</i> , 1996, 65, 61-70.	1.9	23
188	Fluorescently labeled adrenomedullin allows real-time monitoring of adrenomedullin receptor trafficking in living cells. <i>Journal of Peptide Science</i> , 2015, 21, 905-912.	1.4	23
189	Different mode of arrestin-3 binding at the human Y 1 and Y 2 receptor. <i>Cellular Signalling</i> , 2018, 50, 58-71.	3.6	23
190	Adrenomedullin – Current perspective on a peptide hormone with significant therapeutic potential. <i>Peptides</i> , 2020, 131, 170347.	2.4	23
191	Fluorescent Labelled Analogues of Neuropeptide Y for the Characterization of Cells Expressing NPY Receptor Subtypes. <i>Journal of Receptor and Signal Transduction Research</i> , 1997, 17, 407-418.	2.5	22
192	Molecular Characterization of the Human Neuropeptide Y Y ₂ -Receptor. <i>Biochemistry</i> , 1999, 38, 6897-6902.	2.5	22
193	Tetrafunctional Photoaffinity Labels Based on Nakanishi's m-Nitroalkoxy-Substituted Phenyltrifluoromethyl diazirine. <i>Angewandte Chemie - International Edition</i> , 2002, 41, 2293-2297.	13.8	22
194	Access to gram scale amounts of functional globular adiponectin from E. coli inclusion bodies by alkaline-shock solubilization. <i>Biochemical and Biophysical Research Communications</i> , 2010, 398, 32-37.	2.1	22
195	Slime protein profiling: a non-invasive tool for species identification in Onychophora (velvet worms). <i>Journal of Zoological Systematics and Evolutionary Research</i> , 2014, 52, 265-272.	1.4	22
196	G Protein Preassembly Rescues Efficacy of W ^{6.48} Toggle Mutations in Neuropeptide Y ₂ Receptor. <i>Molecular Pharmacology</i> , 2018, 93, 387-401.	2.3	22
197	Improved in Vitro Folding of the Y2 G Protein-Coupled Receptor into Bicelles. <i>Frontiers in Molecular Biosciences</i> , 2017, 4, 100.	3.5	22
198	Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors. <i>Science Advances</i> , 2022, 8, eabm1232.	10.3	22

#	ARTICLE	IF	CITATIONS
199	Structure activity studies of mast cell activation and hypotension induced by neuropeptide Y (NPY), centrally truncated and C-terminal NPY analogues. <i>British Journal of Pharmacology</i> , 1996, 117, 325-332.	5.4	21
200	Carboranes – more than just phenyl mimetics. <i>Pure and Applied Chemistry</i> , 2015, 87, 163-171.	1.9	21
201	Adrenomedullin 2.0: Adjusting Key Levers for Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5695-5705.	6.4	21
202	Modular triazine-based carborane-containing carboxylic acids – synthesis and characterisation of potential boron neutron capture therapy agents made of readily accessible building blocks. <i>Dalton Transactions</i> , 2019, 48, 10834-10844.	3.3	21
203	Semisynthesis and Characterization of the First Analogues of Pro-Neuropeptide Y. <i>ChemBioChem</i> , 2003, 4, 425-433.	2.6	20
204	Localization of Novel Adiponectin Receptor Constructs. <i>Journal of Receptor and Signal Transduction Research</i> , 2006, 26, 647-657.	2.5	20
205	Structural properties of orexins for activation of their receptors. <i>Journal of Peptide Science</i> , 2006, 12, 258-266.	1.4	20
206	Palmitoylated SDF1 – Shows Increased Resistance against Proteolytic Degradation in Liver Homogenates. <i>ChemMedChem</i> , 2011, 6, 193-200.	3.2	20
207	Position and Length of Fatty Acids Strongly Affect Receptor Selectivity Pattern of Human Pancreatic Polypeptide Analogues. <i>ChemMedChem</i> , 2014, 9, 2463-2474.	3.2	20
208	Proteintemplat-vermittelter Acyltransfer: eine chemische Methode für die Markierung von Membranproteinen an lebenden Zellen. <i>Angewandte Chemie</i> , 2014, 126, 10402-10406.	2.0	20
209	Expression, Functional Characterization, and Solid-State NMR Investigation of the G Protein-Coupled GHS Receptor in Bilayer Membranes. <i>Scientific Reports</i> , 2017, 7, 46128.	3.3	20
210	Endothelialization of Titanium Surfaces by Bioinspired Cell Adhesion Peptide Coatings. <i>Bioconjugate Chemistry</i> , 2019, 30, 2664-2674.	3.6	20
211	Molecular Characterization of the Ligand-Receptor Interaction of Neuropeptide Y. <i>Current Medicinal Chemistry</i> , 1999, 6, 1055-1066.	2.4	20
212	High-affinity analogues of neuropeptide Y containing conformationally restricted non-proteinogenic amino acids. <i>Biochemical Society Transactions</i> , 1994, 22, 145-149.	3.4	19
213	Probing of the neuropeptide Y-Y1-receptors interaction with anti-receptor antibodies. <i>FEBS Journal</i> , 1998, 255, 595-603.	0.2	19
214	Differently labeled peptide ligands for rapid investigation of receptor expression on a new human glioblastoma cell line. <i>Peptides</i> , 2000, 21, 1885-1893.	2.4	19
215	Peptide-Mediated Specific Immobilization of Catalytically Active Cytochrome P450 BM3 Variant. <i>Bioconjugate Chemistry</i> , 2016, 27, 1090-1097.	3.6	19
216	The effect of interleukin-8 truncations on its interactions with glycosaminoglycans. <i>Biopolymers</i> , 2018, 109, e23103.	2.4	19

#	ARTICLE	IF	CITATIONS
217	Neuropeptid-Y-Analoga mit $\hat{1}^2$ -Aminocyclopropan-carbonsäure-Einheiten sind die kürzesten linearen und selektiven Peptide am Y1-Rezeptor. <i>Angewandte Chemie</i> , 2003, 115, 212-215.	2.0	18
218	Identification of a potential modification site in human stromal cell-derived factor-1. <i>Biopolymers</i> , 2010, 94, 771-778.	2.4	18
219	Selective Mode of Action of Guanidine-Containing Non-Peptides at Human NPFF Receptors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6124-6136.	6.4	18
220	Oxidative <i>in vitro</i> folding of a cysteine deficient variant of the G protein-coupled neuropeptide Y receptor type 2 improves stability at high concentration. <i>Biological Chemistry</i> , 2013, 394, 1045-1056.	2.5	18
221	High metabolic <i>in vivo</i> stability and bioavailability of a palmitoylated ghrelin receptor ligand assessed by mass spectrometry. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3925-3932.	3.0	18
222	Half-Life Extending Modifications of Peptide YY ₃₆ Direct Receptor-Mediated Internalization. <i>Molecular Pharmaceutics</i> , 2019, 16, 3665-3677.	4.6	18
223	Multifunctional coatings combining bioactive peptides and affinity-based cytokine delivery for enhanced integration of degradable vascular grafts. <i>Biomaterials Science</i> , 2020, 8, 1734-1747.	5.4	18
224	Key Motif to Gain Selectivity at the Neuropeptide Y5-Receptor: A Structure and Dynamics of Micelle-Bound [Ala31, Pro32]-NPY ϵ . <i>Biochemistry</i> , 2002, 41, 8031-8042.	2.5	17
225	Pyridone Dipeptide Backbone Scan To Elucidate Structural Properties of a Flexible Peptide Segment. <i>Journal of the American Chemical Society</i> , 2008, 130, 8326-8336.	13.7	17
226	Cleavage kinetics and anchor linked intermediates in solid phase peptide amide synthesis. <i>International Journal of Peptide and Protein Research</i> , 1991, 38, 146-153.	0.1	17
227	Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation. <i>Molecular Metabolism</i> , 2015, 4, 210-221.	6.5	17
228	Bioorthogonal Labeling of Ghrelin Receptor to Facilitate Studies of Ligand-Dependent Conformational Dynamics. <i>Chemistry and Biology</i> , 2015, 22, 1431-1436.	6.0	17
229	Time-Resolved Tracking of Separately Internalized Neuropeptide Y ₂ Receptors by Two-Color Pulse-Chase. <i>ACS Chemical Biology</i> , 2018, 13, 618-627.	3.4	17
230	Surface-Binding Peptide Facilitates Electricity-Driven NADPH-Free Cytochrome P450 Catalysis. <i>ChemCatChem</i> , 2018, 10, 525-530.	3.7	17
231	Conformation and Aggregation of Selectively PEGylated and Lipidated Gastric Peptide Hormone Human PYY ₃₆ . <i>Biomacromolecules</i> , 2018, 19, 4320-4332.	5.4	17
232	NPY1R-targeted peptide-mediated delivery of a dual PPAR α/β agonist to adipocytes enhances adipogenesis and prevents diabetes progression. <i>Molecular Metabolism</i> , 2020, 31, 163-180.	6.5	17
233	Identification of a novel leptin receptor (LEPR) variant and proof of functional relevance directing treatment decisions in patients with morbid obesity. <i>Metabolism: Clinical and Experimental</i> , 2021, 116, 154438.	3.4	17
234	Photoinduced receptor confinement drives ligand-independent GPCR signaling. <i>Science</i> , 2021, 371, .	12.6	17

#	ARTICLE	IF	CITATIONS
235	Chemerin“ exploring a versatile adipokine. <i>Biological Chemistry</i> , 2022, 403, 625-642.	2.5	17
236	Antibody binding to a collagen type-II epitope gives rise to an inhibitory peptide for autoreactive T cells. <i>European Journal of Immunology</i> , 1992, 22, 1063-1067.	2.9	16
237	The Bioactive Conformation of Neuropeptide Y Analogues at the Human Y2-Receptor. <i>FEBS Journal</i> , 1997, 247, 1019-1028.	0.2	16
238	Identification of neuropeptide Y cleavage products in human blood to improve metabolic stability. <i>Biopolymers</i> , 2007, 88, 182-189.	2.4	16
239	The interaction of neuropeptide Y with negatively charged and zwitterionic phospholipid membranes. <i>European Biophysics Journal</i> , 2009, 38, 663-677.	2.2	16
240	Simultaneous “One Pot”-Expressed Protein Ligation and Cu ^I -Catalyzed Azide/Alkyne Cycloaddition for Protein Immobilization. <i>ChemBioChem</i> , 2011, 12, 2426-2430.	2.6	16
241	On-resin Diels-Alder reaction with inverse electron demand: an efficient ligation method for complex peptides with a varying spacer to optimize cell adhesion. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 4809-4816.	2.8	16
242	Genetically Encoded Photocrosslinkers as Molecular Probes To Study G-Protein-Coupled Receptors (GPCRs). <i>Angewandte Chemie - International Edition</i> , 2012, 51, 310-312.	13.8	15
243	Identification and stabilization of a highly selective gastrin-releasing peptide receptor agonist. <i>Journal of Peptide Science</i> , 2019, 25, e3224.	1.4	15
244	From Scientists to Scientists”Moving <i>Angewandte</i> into the Future. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 12548-12549.	13.8	15
245	Structural Investigations of a Human Calcitonin-Derived Carrier Peptide in a Membrane Environment by Solid-State NMR. <i>Biochemistry</i> , 2004, 43, 12459-12468.	2.5	14
246	The anterograde transport of the human neuropeptide Y2 receptor is regulated by a subtype specific mechanism mediated by the C-terminus. <i>Neuropeptides</i> , 2012, 46, 335-343.	2.2	14
247	Integrating Solid-State NMR and Computational Modeling to Investigate the Structure and Dynamics of Membrane-Associated Ghrelin. <i>PLoS ONE</i> , 2015, 10, e0122444.	2.5	14
248	Strategies for Site-Specific Labeling of Receptor Proteins on the Surfaces of Living Cells by Using Genetically Encoded Peptide Tags. <i>ChemBioChem</i> , 2021, 22, 1717-1732.	2.6	14
249	Imitation and modification of bioactive lead structures via integration of boron clusters. <i>Pure and Applied Chemistry</i> , 2012, 84, 2289-2298.	1.9	13
250	Semi-synthesis of chemokines. <i>Current Opinion in Chemical Biology</i> , 2014, 22, 100-107.	6.1	13
251	A Venomics Approach Coupled to High-Throughput Toxin Production Strategies Identifies the First Venom-Derived Melanocortin Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 8250-8264.	6.4	13
252	Highly Selective Y ₄ Receptor Antagonist Binds in an Allosteric Binding Pocket. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2801-2814.	6.4	13

#	ARTICLE	IF	CITATIONS
253	BIBP 3226, a potent and selective neuropeptide Y Y1-receptor antagonist. Structure-activity studies and localization of the human Y1 receptor binding site. , 1997, , 175-XX.		13
254	One-step procedure for staining of proteins with ruthenium II tris (bathophenanthroline) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50,702 Td (c	2.4	12
255	Tuning peptide affinity for biofunctionalized surfaces. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 69-77.	4.3	12
256	Short-range cytokine gradients to mimic paracrine cell interactions in vitro. Journal of Controlled Release, 2016, 224, 59-68.	9.9	12
257	Ligand-binding and -scavenging of the chemerin receptor GPR1. Cellular and Molecular Life Sciences, 2021, 78, 6265-6281.	5.4	12
258	Structure-activity relationships with neuropeptide Y analogues: a comparison of human Y1-, Y2- and rat Y2-like systems. Regulatory Peptides, 1998, 75-76, 3-8.	1.9	11
259	The First Reporter Gene Assay on Living Cells Green Fluorescent Protein as Reporter Gene for the Investigation of Gi-Protein Coupled Receptors. Molecular Biotechnology, 2002, 21, 009-018.	2.4	11
260	Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125 I][hPP1-17 , Ala31 , Aib32]NPY. British Journal of Pharmacology, 2003, 139, 1360-1368.	5.4	11
261	Novel modified and radiolabelled neuropeptide Y analogues to study Y-receptor subtypes. Neuropeptides, 2004, 38, 153-161.	2.2	11
262	Selective labelling of stromal cell-derived factor 1 with carboxyfluorescein to study receptor internalisation. Journal of Peptide Science, 2010, 16, 568-574.	1.4	11
263	Assessment of a Fully Active Class A G Protein-Coupled Receptor Isolated from <i>in Vitro</i> Folding. Biochemistry, 2011, 50, 9817-9825.	2.5	11
264	Chemerin and Vaspin: Possible Targets to Treat Obesity?. ChemMedChem, 2013, 8, 549-559.	3.2	11
265	A cleavable cytolysin-neuropeptide Y bioconjugate enables specific drug delivery and demonstrates intracellular mode of action. Journal of Controlled Release, 2015, 209, 170-178.	9.9	11
266	Ubiquitin is a versatile scaffold protein for the generation of molecules with <i>de novo</i> binding and advantageous drug-like properties. FEBS Open Bio, 2015, 5, 579-593.	2.3	11
267	Discovery of Small-Molecule Modulators of the Human Y4 Receptor. PLoS ONE, 2016, 11, e0157146.	2.5	11
268	Identification and Characterization of the First Selective Y ₄ Receptor Positive Allosteric Modulator. Journal of Medicinal Chemistry, 2017, 60, 7605-7612.	6.4	11
269	A Deep Hydrophobic Binding Cavity is the Main Interaction for Different Y ₂ R Antagonists. ChemMedChem, 2017, 12, 75-85.	3.2	11
270	Chemical modification of neuropeptide Y for human Y ₁ receptor targeting in health and disease. Biological Chemistry, 2019, 400, 299-311.	2.5	11

#	ARTICLE	IF	CITATIONS
271	Advanced 96-microtiter plate based bioelectrochemical platform reveals molecular short cut of electron flow in cytochrome P450 enzyme. <i>Lab on A Chip</i> , 2020, 20, 1449-1460.	6.0	11
272	Unusually persistent G _i -signaling of the neuropeptide Y2 receptor depletes cellular Gi/o pools and leads to a Gi-refractory state. <i>Cell Communication and Signaling</i> , 2020, 18, 49.	6.5	11
273	Cyclic Analogues of the Chemerin C-Terminus Mimic a Loop Conformation Essential for Activating the Chemokine-like Receptor 1. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3048-3058.	6.4	11
274	Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides. <i>EJNMMI Research</i> , 2020, 10, 16.	2.5	11
275	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii14-ii23.	0.7	11
276	Characterization of the binding site of neuropeptide Y to the rabbit kidney receptor using multiple peptide synthesis. <i>Biochemical Society Transactions</i> , 1992, 20, 847-850.	3.4	10
277	Comparison of Antibodies Directed Against Receptor Segments of NPY-Receptors. <i>Journal of Receptor and Signal Transduction Research</i> , 1999, 19, 379-394.	2.5	10
278	Characterisation of G-Protein-coupled Receptors by Antibodies. <i>Current Medicinal Chemistry</i> , 2000, 7, 897-910.	2.4	10
279	Two motifs with different function regulate the anterograde transport of the adiponectin receptor 1. <i>Cellular Signalling</i> , 2012, 24, 1762-1769.	3.6	10
280	Development of Fluorinated Non-Peptidic Ghrelin Receptor Ligands for Potential Use in Molecular Imaging. <i>International Journal of Molecular Sciences</i> , 2017, 18, 768.	4.1	10
281	Carbaboranylation of Truncated C-Terminal Neuropeptide Y Analogue Leads to Full hY ₁ Receptor Agonism. <i>ChemBioChem</i> , 2018, 19, 2300-2306.	2.6	10
282	Modulation of Human CXCL12 Binding Properties to Glycosaminoglycans To Enhance Chemotactic Gradients. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 5128-5138.	5.2	10
283	Improvement of wound healing by the development of ECM-inspired biomaterial coatings and controlled protein release. <i>Biological Chemistry</i> , 2021, 402, 1271-1288.	2.5	10
284	The Structural Basis of Peptide Binding at Class A G Protein-Coupled Receptors. <i>Molecules</i> , 2022, 27, 210.	3.8	10
285	Novel Y2-selective, reduced-size agonists of neuropeptide Y. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1993, 3, 937-942.	2.2	9
286	From Transcription Profile to Expression: The Signaling Repertoire of the SK-N-MC Neuroepithelioma Cell-Line. <i>Journal of Receptor and Signal Transduction Research</i> , 2004, 24, 257-282.	2.5	9
287	Identification of the dimerisation interface of human interleukin-8 by IL-8-variants containing the photoactivatable amino acid benzoyl-phenylalanine. <i>European Biophysics Journal</i> , 2007, 36, 385-391.	2.2	9
288	Adiponectin receptor 1 interacts with both subunits of protein kinase CK2. <i>Molecular and Cellular Biochemistry</i> , 2011, 356, 185-189.	3.1	9

#	ARTICLE	IF	CITATIONS
289	Quantitative impedimetric NPY-receptor activation monitoring and signal pathway profiling in living cells. <i>Biosensors and Bioelectronics</i> , 2015, 67, 386-393.	10.1	9
290	Rational Design of Dual Peptides Targeting Ghrelin and Y_{2} Receptors to Regulate Food Intake and Body Weight. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4180-4193.	6.4	9
291	Peptide-mediated surface coatings for the release of wound-healing cytokines. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2020, 14, 1738-1748.	2.7	9
292	The Dynamics of the Neuropeptide Y Receptor Type 1 Investigated by Solid-State NMR and Molecular Dynamics Simulation. <i>Molecules</i> , 2020, 25, 5489.	3.8	9
293	An MRM-Based Multiplexed Quantification Assay for Human Adipokines and Apolipoproteins. <i>Molecules</i> , 2020, 25, 775.	3.8	9
294	Site specific biotinylation of the human aldo/keto reductase AKR1A1 for immobilization. <i>Tetrahedron</i> , 2004, 60, 7507-7513.	1.9	8
295	Calcitonin-derived carrier peptide plays a major role in the membrane localization of a peptide-cargo complex. <i>FEBS Letters</i> , 2004, 569, 346-350.	2.8	8
296	Ligand-mimicking Receptor Variant Discloses Binding and Activation Mode of Prolactin-releasing Peptide*. <i>Journal of Biological Chemistry</i> , 2012, 287, 32181-32194.	3.4	8
297	Energetic electron assisted synthesis of highly tunable temperature-responsive collagen/elastin gels for cyclic actuation: macroscopic switching and molecular origins. <i>Scientific Reports</i> , 2019, 9, 12363.	3.3	8
298	Adrenomedullin disulfide bond mimetics uncover structural requirements for AM_{1} receptor activation. <i>Journal of Peptide Science</i> , 2019, 25, e3147.	1.4	8
299	Tuning a modular system – synthesis and characterisation of a boron-rich <i>s</i> -triazine-based carboxylic acid and amine bearing a galactopyranosyl moiety. <i>Dalton Transactions</i> , 2020, 49, 57-69.	3.3	8
300	Chemical Synthesis of TFF3 Reveals Novel Mechanistic Insights and a Gut-Stable Metabolite. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9484-9495.	6.4	8
301	Cyclic Derivatives of the Chemerin C-Terminus as Metabolically Stable Agonists at the Chemokine-like Receptor 1 for Cancer Treatment. <i>Cancers</i> , 2021, 13, 3788.	3.7	8
302	Structure-Activity Relationship Studies: Methods and Ligand Design for G-Protein Coupled Peptide Receptors. <i>Current Protein and Peptide Science</i> , 2006, 7, 335-353.	1.4	7
303	On-Resin Synthesis of an Acylated and Fluorescence-Labeled Cyclic Integrin Ligand for Modification of Poly(lactic-co-glycolic acid). <i>Chemistry and Biodiversity</i> , 2012, 9, 2648-2658.	2.1	7
304	The activity of prolactin releasing peptide correlates with its helicity. <i>Biopolymers</i> , 2013, 99, 314-325.	2.4	7
305	C-terminal motif of human neuropeptide Y4 receptor determines internalization and arrestin recruitment. <i>Cellular Signalling</i> , 2017, 29, 233-239.	3.6	7
306	The Impact of Adrenomedullin Thr22 on Selectivity within the Calcitonin Receptor-like Receptor/Receptor Activity-Modifying Protein System. <i>ChemMedChem</i> , 2018, 13, 1797-1805.	3.2	7

#	ARTICLE	IF	CITATIONS
307	Structural investigations of cell-free expressed G protein-coupled receptors. <i>Biological Chemistry</i> , 2019, 401, 97-116.	2.5	7
308	Cell-Free Expression and Photo-Crosslinking of the Human Neuropeptide Y2 Receptor. <i>Frontiers in Pharmacology</i> , 2019, 10, 176.	3.5	7
309	Biased agonists at the human Y1 receptor lead to prolonged membrane residency and extended receptor G protein interaction. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 4675-4691.	5.4	7
310	Shuttling of Peptide-Drug Conjugates by G Protein-Coupled Receptors Is Significantly Improved by Pulsed Application. <i>ChemMedChem</i> , 2021, 16, 164-178.	3.2	7
311	Synthesis and Application of Peptides as Drug Carriers. <i>Methods in Molecular Biology</i> , 2009, 535, 389-403.	0.9	7
312	Synthesis, Receptor Binding, and Crosslinking of Photoactive Analogues of Neuropeptide Y. <i>Journal of Receptor and Signal Transduction Research</i> , 1995, 15, 473-485.	2.5	6
313	Expressed Protein Ligation for Protein Semisynthesis and Engineering. , 2005, 298, 105-130.		6
314	Molecular Tools to Characterize Adiponectin Activity. <i>Vitamins and Hormones</i> , 2012, 90, 31-56.	1.7	6
315	Analysis of a rare functional truncating mutation rs61757459 in vaspin (SERPINA12) on circulating vaspin levels. <i>Journal of Molecular Medicine</i> , 2013, 91, 1285-1292.	3.9	6
316	Intracellular Trafficking of Neuropeptide Y Receptors. <i>Progress in Molecular Biology and Translational Science</i> , 2015, 132, 73-96.	1.7	6
317	Binding of Natural Peptide Ligands to the Neuropeptide Y ₅ Receptor. <i>Angewandte Chemie - International Edition</i> , 2022, 61, e202108738.	13.8	6
318	Cyclopeptide Analogs for Characterization of the Neuropeptide Y Y2-receptor. <i>Journal of Receptors and Signal Transduction</i> , 1993, 13, 215-228.	1.2	5
319	Molecular ligand-receptor interaction of the NPY/PP peptide family. , 2006, , 35-62.		5
320	Multifunktionale Beschichtung verbessert Zelladhäsion auf Titan durch kooperativ wirkende Peptide. <i>Angewandte Chemie</i> , 2016, 128, 4907-4911.	2.0	5
321	Probing the Y2 Receptor on Transmembrane, Intra- and Extra-Cellular Sites for EPR Measurements. <i>Molecules</i> , 2020, 25, 4143.	3.8	5
322	Cleavage of the vaspin N-terminus releases cell-penetrating peptides that affect early stages of adipogenesis and inhibit lipolysis in mature adipocytes. <i>Adipocyte</i> , 2021, 10, 216-231.	2.8	5
323	Preparation of C-terminally Modified Chemokines by Expressed Protein Ligation. <i>Methods in Molecular Biology</i> , 2013, 1047, 103-118.	0.9	5
324	Expressed Protein Ligation to Obtain Selectively Modified Aldo/Keto Reductases. <i>Protein and Peptide Letters</i> , 2005, 12, 777-781.	0.9	4

#	ARTICLE	IF	CITATIONS
325	Multiple Peptide Synthesis to Identify Bioactive Hormone Structures. , 2007, , 243-288.		4
326	From Scientists to Scientistsâ€”Moving <i>Angewandte</i> into the Future. <i>Angewandte Chemie</i> , 2020, 132, 12648-12649.	2.0	4
327	The ring size of monocyclic ETâ€”1 controls selectivity and signaling efficiency at both endothelin receptor subtypes. <i>Journal of Peptide Science</i> , 2021, 27, e3325.	1.4	4
328	Arrestin-dependent internalization of rhodopsin-like G protein-coupled receptors. <i>Biological Chemistry</i> , 2021, .	2.5	4
329	Introducingâ€” Advisory Editors and New Author Profiles at <i>Angewandte Chemie</i>. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 16720-16722.	13.8	4
330	Orthogonal Peptideâ€”Templated Labeling Elucidates Lateral ET_AR/ET_BR Proximity and Reveals Altered Downstream Signaling. <i>ChemBioChem</i> , 2022, 23, .	2.6	4
331	Proliferative Effect of Calcitonin Gene-related Peptide is Induced by at least Five Proteins as Identified by Proteome Profiling. <i>Chemical Biology and Drug Design</i> , 2007, 69, 14-22.	3.2	3
332	In vitro modification of substituted cysteines as tool to study receptor functionality and structureâ€”activity relationships. <i>Analytical Biochemistry</i> , 2013, 439, 173-183.	2.4	3
333	Peptide Modifications Differentially Alter G Proteinâ€”Coupled Receptor Internalization and Signaling Bias. <i>Angewandte Chemie</i> , 2014, 126, 10231-10235.	2.0	3
334	Recombinant expression and characterization of biologically active protein delta homolog 1. <i>Protein Expression and Purification</i> , 2015, 110, 72-78.	1.3	3
335	Câ€”terminus of a hexapeptidic ghrelin receptor inverse agonist can switch peptide behavior from inverse agonism to agonism. <i>Biopolymers</i> , 2016, 106, 101-108.	2.4	3
336	Development of a ghrelin receptor inverse agonist for positron emission tomography. <i>Oncotarget</i> , 2021, 12, 450-474.	1.8	3
337	Protease-Triggered Release of Stabilized CXCL12 from Coated Scaffolds in an Ex Vivo Wound Model. <i>Pharmaceutics</i> , 2021, 13, 1597.	4.5	3
338	Towards Understanding the Free and Receptor Bound Conformation of Neuropeptide Y by Fluorescence Resonance Energy Transfer Studies. <i>Chemical Biology and Drug Design</i> , 2009, 73, 573-583.	3.2	2
339	Introducingâ€” Advisory Editors and New Author Profiles at <i>Angewandte Chemie</i>. <i>Angewandte Chemie</i> , 2021, 133, 16856-16858.	2.0	2
340	Peptides as Modulators of Serpin Action. , 2015, , 29-45.		2
341	Anthrax: Terror im Immunsystem. <i>Nachrichten Aus Der Chemie</i> , 2002, 50, 42-45.	0.0	1
342	Surface-Binding Peptide Facilitates Electricity-Driven NADPH-Free Cytochrome P450 Catalysis. <i>ChemCatChem</i> , 2018, 10, 487-487.	3.7	1

#	ARTICLE	IF	CITATIONS
343	Highlight: Protein states with cell biological and medicinal relevance. <i>Biological Chemistry</i> , 2013, 394, 919-920.	2.5	0
344	Different Y2 receptor antagonists share the same deep, hydrophobic binding pocket. <i>Neuropeptides</i> , 2016, 55, 16-17.	2.2	0
345	Influence of distinct motifs within the carboxyl-terminus of the human neuropeptide Y4 receptor on internalization and arrestin3 recruitment. <i>Neuropeptides</i> , 2016, 55, 23.	2.2	0
346	Protease-Triggered Release of Stabilized CXCL12 from Coated Biomaterials for Improved Implant Integration and Wound Healing. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
347	Specific mutations on the receptor-binding interface of non-visual arrestins differently affect recruitment by the NPY receptor family. <i>FASEB Journal</i> , 2013, 27, 1031.3.	0.5	0
348	Binding of Natural Peptide Ligands to the Neuropeptide Y5 Receptor. <i>Angewandte Chemie</i> , 2022, 134, e202108738.	2.0	0
349	Analytik synthetischer Peptide. , 2022, , 643-657.		0